FRM
RLAY icon

Fox Run Management’s Relay Therapeutics RLAY Stock Holding History

Fox Run Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,284
Closed -$143K – 1247
2026
Q1 		$143K Sell
15,284
-44,919
-75% -$402K 0.03% 808
2025
Q4 		$509K Buy
+60,203
New +$430K 0.08% 493
2024
Q4 		– Sell
-18,553
Closed -$131K – 1134
2024
Q3 		$131K Sell
18,553
-17,247
-48% -$129K 0.03% 720
2024
Q2 		$233K Buy
35,800
+9,409
+36% +$64.3K 0.04% 621
2024
Q1 		$219K Buy
26,391
+14,200
+116% +$139K 0.05% 612
2023
Q4 		$134K Buy
+12,191
New +$103K 0.03% 669

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Fox Run Management's RLAY Position: Q2 2026 in Review

Fox Run Management sold out of Relay Therapeutics (RLAY) in Q2 2026, closing a stake of 15,284 shares — an estimated $143K sold.

Fox Run Management first reported a position in RLAY in Q4 2023 and held it in 6 quarters. The position peaked at $509K in Q4 2025. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Fox Run Management reported no remaining Relay Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Fox Run Management sold 15,284 Relay Therapeutics shares in Q2 2026, an estimated $143K.
  • Fox Run Management first reported a position in Relay Therapeutics in Q4 2023 and held it in 6 quarters.
  • Fox Run Management's Relay Therapeutics position peaked at $509K in Q4 2025.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.